

# 1 Integrated Single-Cell Analysis of Multicellular Immune Dynamics

## 2 during Hyper-Acute HIV-1 Infection

3 Samuel W. Kazer<sup>1,2,3</sup>, Toby P. Aicher<sup>1,2,3</sup>, Daniel M. Muema<sup>4,5</sup>, Shaina L. Carroll<sup>6</sup>, Jose Ordovas-  
4 Montanes<sup>1,2,3,7</sup>, Carly G. K. Ziegler<sup>1,2,3,8</sup>, Sarah K. Nyquist<sup>1,2,3,9</sup>, Emily B. Wong<sup>4,10</sup>, Nasreen Ismail<sup>5</sup>,  
5 Mary Dong<sup>1</sup>, Amber Moodley<sup>1,5</sup>, Krista L. Dong<sup>3,5</sup>, Zaza M. Ndhlovu<sup>1,4,5,11</sup>, Thumbi Ndung'u<sup>1,4,5,12</sup>,  
6 Bruce D. Walker<sup>1,5,11,†,\*</sup>, and Alex K. Shalek<sup>1,2,3,8,9,†,\*</sup>

## 7 Affiliations

8 <sup>1</sup>Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA

9 <sup>2</sup>Institute for Medical Engineering and Science (IMES), Department of Chemistry, and Koch  
10 Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,  
11 MA, USA

12 <sup>3</sup>Broad Institute of MIT and Harvard, Cambridge, MA, USA

13 <sup>4</sup>African Health Research Institute, Durban, South Africa

14 <sup>5</sup>HIV Pathogenesis Programme, Nelson R. Mandela School of Medicine, Doris Duke Medical  
15 Research Institute, University of KwaZulu-Natal, Durban, South Africa

16 <sup>6</sup>Department of Molecular and Cell Biology, University of California, Berkeley, CA, USA

17 <sup>7</sup>Division of Infectious Diseases and Division of Gastroenterology, Boston Children's Hospital,  
18 Boston, MA, USA

19 <sup>8</sup>Division of Health Sciences and Technology, Harvard Medical School, Boston, MA, USA

20 <sup>9</sup>Program in Computational and Systems Biology, Massachusetts Institute of Technology,  
21 Cambridge, MA, USA

22 <sup>10</sup>Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Harvard  
23 Medical School, Boston, MA, USA; Division of Infection and Immunity, University College London,  
24 London, UK

25 <sup>11</sup>Howard Hughes Medical Institute, Chevy Chase, MD, USA

26 <sup>12</sup>Max Planck Institute for Infection Biology, Berlin, Germany

27 <sup>†</sup>These authors contributed equally to this work.

28 \*Corresponding Author Emails: [shalek@mit.edu](mailto:shalek@mit.edu) (A.K.S.); [BWALKER@mgh.harvard.edu](mailto:BWALKER@mgh.harvard.edu) (B.D.W)

29

30 **ABSTRACT**

31 Cellular immunity is critical for controlling intracellular pathogens, but the dynamics and  
32 cooperativity of the evolving host response to infection are not well defined. Here, we apply single-  
33 cell RNA-sequencing to longitudinally profile pre- and immediately post-HIV infection peripheral  
34 immune responses of multiple cell types in four untreated individuals. Onset of viremia induces a  
35 strong transcriptional interferon response integrated across most cell types, with subsequent pro-  
36 inflammatory T cell differentiation, monocyte MHC-II upregulation, and cytolytic killing. With  
37 longitudinal sampling, we nominate key intra- and extracellular drivers that induce these  
38 programs, and assign their multi-cellular targets, temporal ordering, and duration in acute  
39 infection. Two individuals studied developed spontaneous viral control, associated with initial  
40 elevated frequencies of proliferating cytotoxic cells, inclusive of a previously unappreciated  
41 proliferating natural killer (NK) cell subset. Our study presents a unified framework for  
42 characterizing immune evolution during a persistent human viral infection at single-cell resolution,  
43 and highlights programs that may drive response coordination and influence clinical trajectory.

44

45 ***Introduction***

46 Understanding the dynamics of host-pathogen interactions during acute viral infection in  
47 humans has been hindered by limited sample availability and technical complications associated  
48 with comprehensively profiling heterogeneous cellular ensembles. To date, microarray and bulk  
49 transcriptomic studies of yellow fever vaccination<sup>1</sup> and influenza infection<sup>2</sup> have highlighted  
50 complex cellular responses that vary as a function of time, largely characterizing a common  
51 systemic interferon stimulated gene (ISG) program. In each instance, additional insights might be  
52 gleaned through more sensitive, discretized systems-approaches that can elucidate the  
53 contributions of individual cellular components and nominate features that drive productive  
54 responses essential to improve vaccines.

55 Recently, high-throughput single-cell RNA-sequencing (scRNA-Seq) has emerged as a  
56 powerful tool to characterize, transcriptome-wide, complex human systems in health and disease  
57 at single-cell resolution<sup>3-9</sup>. When applied to a collection of samples across a disease setting, this  
58 approach provides a platform for investigating cell types, states, interactions, and drivers  
59 associated with that disease; this information can be used to develop testable hypotheses on  
60 therapeutic modulations that may ameliorate disease state<sup>7,8</sup>. Meanwhile, within an individual,  
61 longitudinal sampling provides an opportunity to decipher, at unprecedented resolution and  
62 absent potentially confounding inter-individual variability<sup>7</sup>, shifts in these same variables, and to

63 associate observed changes with internal or external perturbations<sup>10–12</sup>. Such sampling of a host's  
64 exposure to a pathogen could provide foundational insights into essential cellular response  
65 features and their coordination, empowering the rational design of improved prophylactic  
66 interventions.

67 Illustratively, a better understanding of the interplay between innate and adaptive immune  
68 responses at the very earliest stages of a viral infection, and its impact on long-term disease,  
69 could reveal principles to accelerate prevention efforts. Human Immunodeficiency Virus (HIV) has  
70 been the subject of thorough study, and thus is a well-considered model system for examining  
71 host responses to a pathogen. Moreover, although the development of antiretroviral therapy  
72 (ART)<sup>13</sup>, as well as implementation of pre-exposure prophylaxis (PrEP)<sup>14</sup> and combination  
73 prevention efforts, has improved the lives of persons living with HIV, increased life expectancies,  
74 and reduced the number of new infections, there were still 2 million new cases of HIV-1 infection  
75 in 2017<sup>15</sup>. This highlights a pressing need for effective HIV vaccines informed by an understanding  
76 of natural host-pathogen dynamics.

77 Here, we apply scRNA-Seq to perform an integrated longitudinal analysis of implicated  
78 cell programs and drivers during the critical earliest stages of HIV infection. By examining  
79 individuals in the Females Rising through Education, Support and Health (FRESH) study<sup>16,17</sup> – a  
80 unique prospective cohort of uninfected young women at high risk of contracting HIV who are  
81 monitored for acute viremia by twice weekly plasma sampling – and focusing on those who were  
82 enrolled at a time when standard of care did not include treatment during acute disease, we  
83 comprehensively examine untreated cellular immune dynamics during the evolution of hyper-  
84 acute infection into chronic viremia. Among over 65,000 cells obtained from repeated sampling of  
85 peripheral blood, we identify cell types, states, gene modules, and molecular drivers associated  
86 with coordinated immune responses to a viral pathogen. Further, these data suggest candidate  
87 cellular features that may influence the magnitude of chronic viremia, known to predict long-term  
88 infection outcome. Overall, our longitudinal, granular approach captures multiple dynamic and  
89 coordinated immune responses – both shared and distinct between cell types and individuals –  
90 and provides a framework for their elucidation in health and disease.

91

## 92 **Results**

### 93 **Longitudinal single-cell transcriptomic profiling captures major and granular immune 94 subsets in hyper-acute infection**

95        In order to globally and longitudinally examine host immune responses during a hyper-  
96 acute infection, we performed scRNA-Seq on peripheral blood mononuclear cells (PBMCs) from  
97 four individuals enrolled in FRESH who became infected with HIV, assessing multiple timepoints  
98 from pre-infection through one year following initial detection of viremia (Fig. 1A, table S1). In our  
99 study, hyper-acute infection refers to timepoints at and prior to peak-viral load, whereas acute  
100 infection refers to timepoints after peak viral load but before 6 months. Samples were processed  
101 in duplicate using Seq-Well<sup>18</sup> – a portable, low-input massively-parallel scRNA-Seq platform  
102 designed for clinical specimens – allowing for robust single-cell transcriptional analysis of PBMC  
103 subsets. All individuals studied demonstrated the expected rapid rise in plasma viremia and drop  
104 in CD4+ T cell counts that typify hyper-acute and acute HIV infection (Fig. 1B). Among all  
105 individuals, we captured 65,842 cells after eliminating low quality cells and multiplets (see  
106 Methods), with an average of 2,195 cells per individual per timepoint. Alignment to a combined  
107 human and HIV genome at peak infection timepoints yielded few reads mapping to HIV; therefore,  
108 alignment for all samples was conducted using a human-only reference.

109        To assign cellular identity, we performed variable gene selection, dimensionality reduction,  
110 clustering, and embedding *en masse* across data collected from all individuals and timepoints  
111 (see Methods). Samples were combined for cell type/phenotype identification to find common  
112 transcriptional features of ubiquitous cell subsets, and to improve statistical power on classifying  
113 small/rare cell types. Importantly, combined analyses yielded few individual-specific features in  
114 the resulting clustering and embedding, suggesting that disease biology, rather than technical  
115 batch, is the main driver of variation and subsequent clustering (Fig. 1D, Fig. S1A,B). We  
116 annotated identified clusters by comparing differentially expressed (DE) genes that defined each  
117 to known lineage markers and previously published scRNA-Seq datasets<sup>19–21</sup> (Fig. S1C, see  
118 Table S2 for list of DE markers). These clusters recapitulated several well-annotated PBMC  
119 subsets (Fig. 1C), in addition to revealing phenotypic groupings of monocytes (anti-viral,  
120 inflammatory, non-classical) and cytotoxic T cells (CD8+ CTL, proliferating; see Fig. S1D). Thus,  
121 we readily and reproducibly mapped the cellular players and phenotypes present along the course  
122 of disease progression.

123

#### 124 **Cell frequency over time is readily obtained from transcript-assigned cellular identity**

125        We next examined cellular dynamics over the course of infection, beginning with a pre-  
126 infection time point. Onset of HIV infection is typically accompanied by an initial depletion of CD4+  
127 T cells in the blood and a subsequent small rebound before continued depletion in chronic

128 infection<sup>22</sup>. To ensure that our estimated frequencies would recapitulate conventional  
129 measurements of our samples, in parallel, we employed flow cytometry to independently establish  
130 the frequencies of T cell subsets (Fig. S2A). Linear regression of the measured CD3<sup>+</sup>CD4<sup>+</sup> and  
131 CD3<sup>+</sup>CD8<sup>+</sup> flow populations (% of total CD45<sup>+</sup> cells) with their respective single-cell transcriptome  
132 clusters (% of total single cells) across time yielded strong correlations (linear regression, F-test):  
133 average CD4<sup>+</sup> –  $R^2 = 0.491$ ,  $p = 0.0416$ ; average CD8<sup>+</sup> –  $R^2 = 0.665$ ,  $p = 0.00158$  (Fig. 1E).  
134 Subsequently, we calculated frequencies for the other cell types in our scRNA-Seq data as a  
135 function of time (Fig. S2B). In each individual, we measured an expansion in monocytes at HIV  
136 detection and in NK cells that peaked at 3- or 4-weeks post-detection, in-line with studies of  
137 influenza and murine cytomegalovirus (MCMV) demonstrating expansion and recruitment of  
138 monocytes and NK cells to sites of infection, though on shorter time-scales<sup>23–25</sup>. Altogether, our  
139 data elucidate dynamic temporal shifts in the abundance of different cellular subsets during hyper-  
140 acute and acute HIV infection aligned with flow cytometry; more importantly, with whole  
141 transcriptome information, they enable further global characterization of subcellular activity within  
142 and between these subsets.

143

#### 144 **Discovering structured variation in cell phenotypes over time in response to infection**

145 To understand how the identified cell types – monocytes, dendritic cells (DCs),  
146 plasmablasts, B cells, natural killer (NK) cells, CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, and proliferating T cells  
147 (a sub-cluster of CTLs, see Fig S1D) – varied in phenotype over the course of infection, we  
148 assessed coordinated changes in gene expression within each cell type that significantly varied  
149 in time. Since the immune responses and time courses of infection were heterogeneous among  
150 participants due to our sampling scheme and natural human variability, we performed analyses  
151 on an individual-by-individual and cell-type-by-cell-type basis. In this way, our results are sensitive  
152 to both intra- and inter-individual changes in gene expression.

153 To identify tightly co-regulated modules (M) of genes for each type for each individual, we  
154 applied weighted gene correlation network analysis (WGCNA)<sup>26,27</sup> on all cells classified as a  
155 particular cell type across all timepoints (Fig. 2A; see Methods for details). Strongly correlated  
156 gene modules (permutation test for within-module similarity, FDR corrected  $q < 0.05$ ) were then  
157 tested for significant variation over time by scoring cells at each timepoint against the genes within  
158 a module, followed by tests for shifts in score distribution between pairs of timepoints (Wilcoxon  
159 rank sum test, FDR corrected  $q < 0.05$ ). This generated 0-8 temporal modules per cell type (for a

160 list of all significant modules see Table S3 for gene membership and Table S4 for median module  
161 scores over time).

162 Across cell types within an individual, these gene program trajectories demonstrated  
163 common transient patterns along the course of infection, indicating the utility of this approach in  
164 identifying groups of genes acting in concert. While a similar approach is possible using bulk RNA-  
165 seq data, here, we are powered to identify temporally similar modules active in distinct subsets of  
166 cells both within and across time. Compared to a directed approach, this discovery-based  
167 identification of temporally-variant modules enables unbiased selection of coordinated genes and  
168 pathways, and immediately reveals differences in response dynamics among cell types, states,  
169 and individuals.

170

171 **Temporal module analysis reveals shared and unique responses to interferon across cell**  
172 **subsets near peak viremia**

173 With distinct, temporally-variant modules across all cell types and individuals in hand, we  
174 next sought to understand these response modules and their association with plasma viral load,  
175 the main clinical parameter linked with disease progression rate and clinical outcome<sup>28,29</sup>.  
176 Beginning with one individual (P1), we identified a set of 6 significant gene modules spanning  
177 multiple cell types that all shared their highest relative module score at the peak viremia timepoint  
178 (Fig. 2B). Upon inspection of the genes within each, we uncovered a core set of genes shared  
179 among the modules from all cell types: *IFI27*, *IFI44L*, *IFI6*, *IFIT3*, *ISG15*, and *XAF1*. These genes,  
180 in addition to many others belonging to one or multiple of these peak viral load modules, are all  
181 induced by type I interferon (IFN-I) stimulation in cell lines and ex-vivo primary cells<sup>30-32</sup> (Fig. 2C,  
182 Fig. S3A). Since these modules were generated *de-novo*, our results also report cell type specific  
183 genes and functions that correlate with the core measured IFN response signature: anti-viral  
184 activity (*CXCL10*, *DEFB1*, *IFI27L1*) in monocytes<sup>33,34</sup>, DC activation (*PARP9*, *STAT1*) likely  
185 through sensing of HIV by pattern recognition receptors and interferon by interferon receptors<sup>35-</sup>  
186<sup>37</sup>, differentiation of naïve CD4+ T cells (*CD52*, *TIGIT*, *TRAC*) potentially into HIV-specific T helper  
187 cells<sup>38-41</sup>, and NK cell trafficking (*CX3CR1*, *ICAM2*) shown to occur in other viral infections<sup>42-44</sup>.

188 As transcriptional work in humans has been limited to late-acute stage and treated  
189 infection<sup>45</sup>, we sought to contextualize our data against the massive IFN response measured in  
190 acute SIV infection<sup>46-49</sup>, specifically in rhesus macaques (RM, see Fig. S3B)<sup>47</sup>. In SIV models,  
191 natural hosts of the infecting virus (e.g., sooty mangabeys) resolve IFN immune activation more

192 quickly than susceptible hosts, positing that time to resolution may reflect future control in chronic  
193 infection (>180 days). By comparison, we find that many IFN stimulated genes induced in RM for  
194 2+ weeks arise and resolve within one week (i.e., upregulate at one timepoint). Here, we are  
195 powered to assign the cells expressing these various response genes. For example, upregulation  
196 of RIG-I (*DDX58*) is limited to myeloid cells – though RIG-I signaling has been shown to be  
197 subverted by HIV<sup>50</sup> – whereas only CD4<sup>+</sup> T cells exhibit higher levels of *STAT2*, suggesting a  
198 polarization towards a T<sub>H</sub>1 phenotype<sup>51</sup>.

199 Subsequently, we examined the expression of *IRF7*, one of the interferon regulatory  
200 factors that is responsible for anti-viral mediated IFN-I production in SIV/HIV<sup>52,53</sup> and other viral  
201 infections, to determine which cells might be generating this pervasive wave of IFN. In individual  
202 P1, almost all cell types demonstrated higher expression of *IRF7* compared to pre-infection and  
203 1-year timepoints (Fig. S3C), highlighting the pervasiveness of IFN-I in response to high levels of  
204 viremia and potentially indicative of the positive feedback loop it induces<sup>54–56</sup>. Since plasmacytoid  
205 DCs (pDCs) are known to produce IFN- $\alpha$  and IFN- $\beta$  in response to HIV<sup>57</sup>, we also assayed single  
206 pDCs at peak viremia and 1-year post-infection using a plate-based scRNA-Seq method  
207 compatible with enrichment by FACS (Smart-Seq2<sup>58</sup>) (Fig. S4A). At both times, type I IFNs were  
208 undetectable (see Supplementary Text). Comparing pDCs between them, we observe modestly  
209 increased expression of *IRF7* at peak viremia (Wilcoxon rank sum test, FDR corrected  $q < 1$ ,  
210  $\log(\text{Fold Change}) = 0.42$ ). However, these cells also upregulated several ISGs that were present  
211 in the modules of other cell types (Fig. S4B).

212 We next sought to identify whether similar gene expression programs typified responses  
213 in the other three individuals assayed. We readily discovered a similar set of modules around the  
214 time of peak viremia in each individual (Fig. 2D and Fig. S3D), as well as shared responses among  
215 pDCs (Fig. S4C). Comparing modules across our cohort, we noted common response genes  
216 (present in 3 or more cell-types) either shared (*ISG15*, *IFIT3*, *XAF1*) or specific (*APOBEC3A*,  
217 *IFI27*, *STAT1*) to subsets of individuals, suggesting potential core programming and the possibility  
218 for the same immune drivers to induce distinct gene responses (Fig. S4D). Finally, to confirm the  
219 presence of downstream cytokines from IFN stimulation, we measured MIG (CXCL9) and IP10  
220 (CXCL10) levels in plasma at pre-infection, peak viremia, and 9-months post infection (Fig. 2E;  
221 Methods). All four individuals demonstrated higher levels of IP10 at peak viremia, and three  
222 demonstrated elevated levels of MIG. Together, these data highlight the ability of our approach  
223 to ascertain a short, pervasive wave of IFN responses in most peripheral immune cells that  
224 coincides with, or precedes, peak viremia in hyper-acute HIV infection. Moreover, we uncover

225 nuanced differences among individuals and cellular subsets in this response, as might be  
226 expected for an infection associated with diverse clinical courses (e.g., differences in plasma  
227 viremia; Fig. 1B).

228

229 **Individuals demonstrate diverse, yet coordinated, immune responses during the first**  
230 **month of infection**

231 To investigate other groups of temporally similar modules, we next applied fuzzy c-means  
232 clustering<sup>59,60</sup> to the median module scores at each timepoint across all cell types on an individual-  
233 by-individual basis to generate clusters of modules, hereafter referred to as meta-modules (MMs).  
234 We subsequently grouped these MMs by temporal shape (Fig. S5 and see Methods for choice of  
235 c). MMs represent gene programming in distinct cell types that demonstrate coordinated temporal  
236 patterns – here, various cell-types responding simultaneously to infection – enabling us to link  
237 discrete transcriptional responses to their propagators. In addition to the aforementioned MM that  
238 contained the majority of the IFN response modules (labeled MM3), the only other MM that  
239 spanned the majority of cell types was one enriched for ribosomal protein coding genes (labeled  
240 MM5, see table S3) – known to indicate cellular quiescence<sup>61</sup>. MM5 demonstrated temporal  
241 profiles defined by minimum module scores (i.e., significantly downregulated) around peak  
242 viremia, anti-concordant with the immune activation (i.e., significant upregulation) seen in MM3.

243 Another MM that shared similar temporal immune responses across individuals was MM1,  
244 comprised of responses sustained throughout one-month post-detection. In at least 2 of the 4  
245 individuals studied, we identified sustained response modules with shared genes in CD4<sup>+</sup> T cells,  
246 monocytes, NK cells, CTLs, and proliferating T cells (Fig. 3A-E, see table S5 for overlapping  
247 genes). While DCs and B cells also expressed multiple modules within this MM, some modules  
248 had low MM membership scores and were excluded (membership < 0.25, labeled with † in Fig.  
249 S5) or did not share any genes across individuals (Fig. S6A and Supplementary Text).

250 As each module within MM1 is distinct, we performed gene set enrichment analyses (see  
251 Methods) to discern if, in addition to sharing genes, modules from the same cell type shared  
252 functional annotations across individuals (Fig. 3A-E). In every cell type, modules across  
253 individuals were significantly enriched for many of the same underlying pathways (see table S6  
254 for full list), despite slightly variable temporal dynamics and unique gene membership. CD4<sup>+</sup> T  
255 cells expressed genes associated with non-classical viral entry by endocytosis<sup>62</sup> as well as  
256 adhesion, potentially suggesting migration and viral dissemination throughout the body.

257 Monocytes expressed genes associated with antigen presentation and IL-4 signaling (mainly  
258 HLA-DR subunits), which may reflect generalized interferon responses, or the potential to  
259 promote active T helper and CTL responses. NK cells, CTLs, and proliferating T cells all  
260 upregulated genes associated with killing of target cells by perforin and granzyme release,  
261 highlighting the joint role of innate and adaptive cells in combating viremia (see Table S5 and Fig.  
262 S6B for all shared responses across cell types)<sup>63,64</sup>. Thus, our results indicate common functional  
263 enrichments supported by gene sets that vary across cell types and individuals in response to  
264 infection.

265

## 266 **Distinct cell types respond to common and unique upstream drivers induced in infection.**

267 To identify common and cell-type specific inducers of these measured transient responses  
268 extending past peak viremia, we generated a list of predicted upstream drivers of each module  
269 (see Table S6). Selecting highly significant hits in at least two modules, we drew a network of  
270 putative upstream drivers (nodes) colored by significance in each cell type with edges connecting  
271 nodes with shared enriched genes (Fig. 3F, Fig. S6C, and see Methods). Strikingly, IFN- $\alpha$  and  
272 IFN- $\gamma$  are predicted drivers of these sustained responses for all five cell types even though these  
273 modules do not contain the typical ISGs; in chronic HIV infection, prolonged IFN-I stimulation has  
274 been shown to maintain viral suppression but also blunt other immune functions in a humanized  
275 mouse model<sup>65,66</sup>. Matching Luminex data confirmed elevated levels of IP-10 and MIG at one-  
276 month post HIV detection (Fig. S6D). IL-15 and IL-2, known to induce T and NK cell proliferation  
277 but to lead to defects in chronic infection<sup>67-69</sup>, were enriched as drivers for all lymphocytes  
278 explored. However, they also shared enriched genes with several other interleukins, including IL-  
279 4, IL-12 (also elevated in plasma, see Fig. S6D), and IL-21. Interestingly, only CD4 $^{+}$  T cell modules  
280 were enriched for TNF, IL-1B, and OSM, suggesting the directed induction of pro-inflammatory T  
281 helper cells<sup>70</sup>. Meanwhile, monocytes and NK cells were enriched for CIITA and EBI3 (a subunit  
282 of IL-27), which regulate MHC-II and MHC-I genes, respectively<sup>71,72</sup>.

283 We also contextualized observed responses to these upstream drivers temporally by re-  
284 scoring against enriched genes for each driver. This analysis revealed variable kinetics in the  
285 onset, intensity, and length of immune responses across different cell types (Fig. 3G, Fig. S7).  
286 We note the following gene-programming upregulation trends in most individuals: CD4 $^{+}$  T cells  
287 are active from before peak viremia throughout 3-4 weeks post infection, and CTL and  
288 proliferating T cell programs are induced for 2-3 weeks around peak viremia, whereas NK cell  
289 and monocyte activity extends throughout the first month of infection.

290         Based on shared cell-type enrichments, genes, and functions, we summarize the  
291         multitude of common immune responses displaying sustained gene expression over the course  
292         of first month of HIV infection, and their potential drivers, across individuals (Fig. 3H). While the  
293         IFN stimulated gene programs do not extend past hyper-acute infection, our data suggest that  
294         persistent IFN activation could manifest in different ways in each cell type, leading long-term to  
295         previously shown dysfunction partially mediated by IFN in chronic infection<sup>73</sup>. This analysis also  
296         support more complex cytokine interactions – some previously described as synergistic (e.g. IL-  
297         2 & IL-18<sup>74</sup>) or antagonistic (e.g. IL-6 & IL-27<sup>75</sup>) – occurring in acute infection, and delineates how  
298         they may affect various cell types. Though dozens of cytokines are known to elevate in plasma  
299         during acute HIV infection<sup>76</sup>, here we present a putative schematic of which cell types they  
300         modulate alongside other extracellular proteins and transcription factors active during this time  
301         frame. Furthermore, our analysis establishes a blueprint of multi-cellular responses to several  
302         stimuli along the course of hyper-acute and acute infection to be edified by application to other  
303         pathogens.

304

### 305         **Two instances of temporally similar modules within a cell type discerned by scRNA-Seq**

306         After discovering temporally variant modules in our dataset, we observed a few sets that  
307         demonstrated similar temporal response patterns in a given cell type, but were not combined into  
308         a single module by our framework. We thus sought to understand how these modules might be  
309         linked by looking across single cells for module co-expression. Here, single-cell expression data  
310         are essential to distinguish response circuitry among cells.

311         The clearest example of multiple modules being co-expressed with the same temporal  
312         pattern in the same cell type from our analysis was the NK activated M3 module (*CCL3*, *CCL4*,  
313         *CD38*) and the cytotoxic M4 module (*PRF1*, *GZMB*, *HLA-A*) in P3 (Fig. 3D), both part of MM1.  
314         Enrichment analysis demonstrated little overlap between the significant pathways associated with  
315         these modules, implying orthogonal biological function. We therefore investigated whether the  
316         gene programs for these modules were highly co-expressed in the same single cells and thus co-  
317         varied among single cells across time (Fig. S8A). While we did not observe differential  
318         simultaneous upregulation of these modules between time points, we found variation in the  
319         correlation of cell-scores for the pair as a function of time across single cells, with the strongest  
320         correlation one to two weeks after HIV detection (Fig. S8B). Variation in the correlation of M3 and  
321         M4 may reflect a synergizing of these gene programs<sup>77</sup> within NK cells to combat HIV as viremia  
322         declines post peak.

323        In examining MM3 (Fig. S5) – containing the majority of the IFN response modules – we  
324    observed that P3 also exhibited a set of temporally similar modules in monocytes (M1 & M3);  
325    however, these modules did not variably correlate in expression score as a function of time.  
326    Instead, these gene programs were highly co-expressed but only at HIV-detection (Fig. S8C-D).  
327    Gene set analysis readily demonstrated that monocyte M1 consisted of IFN response genes,  
328    while M3 was enriched for genes associated with inflammation (Fig. S8E). IFN has been shown  
329    to stunt the production of pro-inflammatory cytokines in monocytes similar to the phenotype  
330    observed in these cells in viremic persons<sup>78,79</sup>, but the co-expression of anti-viral and pro-  
331    inflammatory signals in the same single cells has not yet been described to our knowledge. As  
332    these module scores are generated independently for each single cell, individual monocytes in  
333    this person at the time of HIV detection are simultaneously expressing both anti-viral and  
334    inflammatory gene programs. Critically, our longitudinal granular, single-cell approach facilitates  
335    the study of variation in gene module correlation and co-upregulation, suggesting key cellular  
336    circuitry, and its coordination, during response to infection.

337

338    **One individual who naturally controls infection displays a polyfunctional subset of**  
339    **monocytes at HIV detection**

340        Intrigued by the appearance of these polyfunctional monocytes in one individual, we next  
341    explored whether the other individuals assayed developed similar cells after infection. Scoring  
342    monocytes from each individual on inflammatory and anti-viral gene lists derived from discovered  
343    modules (Fig. S9A), we were unable to identify these polyfunctional monocytes in the other three  
344    individuals (Fig. 4A-B, Fig. S9B-C). In fact, looking at structured gene variation in monocytes over  
345    time in principal component analysis (PCA) space revealed that the major axis of variation (PC1)  
346    in P1 and P2 not only reflected sample timepoint, but also separated monocytes based on their  
347    expression of anti-viral and inflammatory genes. In P3 and P4, however, these gene programs  
348    contributed to different principal components, suggesting their independence in defining  
349    monocyte phenotype.

350        In all four individuals, we saw dramatic structuring of the monocytes in PC space by time.  
351    Specifically, monocytes sampled at HIV detection (0 weeks) or 1-week post-detection were  
352    strongly separated along either PC1 or PC2, indicating a pervasive hyper-acute response to  
353    infection. Interestingly, non-classical monocytes (see Fig. S1D and Table S2), which may be more  
354    susceptible to infection<sup>80</sup>, displayed disparate temporal dynamics across individuals, even though  
355    they drove significant variation in PCA space (Fig. S9D). Comparing DE genes at these peak

356 response timepoints (vs. pre-infection) highlighted not only the specificity of the co-  
357 inflammatory/anti-viral monocytes to P3, but also other person specific differences in monocyte  
358 phenotype (Fig. 4C). Gene set analysis on upregulated genes in each individual confirmed that  
359 monocytes in all individuals produced strong anti-viral factors (e.g., *RIG-I*, *APOBEC3B*, *MX1*) with  
360 significant enrichment (MHC hypergeometric test,  $q < 0.001$ ) for response to IFN- $\alpha$  and IFN- $\gamma$  (Fig.  
361 4D). Moreover, corroborating the scoring on inflammatory genes, only P2 and P3 were  
362 significantly enriched for inflammatory responses, and only P3 for TNF signaling via NF- $\kappa$ B (MHC  
363 hypergeometric test,  $q < 0.001$ ). In fact, P1 and P2 demonstrated downregulation of genes  
364 associated with inflammation compared to pre-infection.

365 Subsequently, we investigated known clinical parameters in our cohort for features of  
366 infection that might be related to the appearance of these polyfunctional cells. As the level of viral  
367 load in chronic infection correlates with disease outcome<sup>28</sup>, we compared the viral load setpoints  
368 of these individuals at 1.8, 2.3, and 2.75 years after HIV detection. Two of the four individuals (P3  
369 & P4) maintained low levels of viremia (< 1,000 viral copies (vc)/mL) out to 2.75 years in the  
370 absence of ART (Fig. 4E). HIV infected persons who naturally maintain low levels of viremia in  
371 chronic infection (controllers) have been shown to have enhanced immune responses in chronic  
372 infection<sup>7,81,82</sup>. However, whether early events in acute HIV infection reflect or contribute to long-  
373 term control is unknown. In the hyper-acute monocyte responses (Fig. 4C), we found a small set  
374 of upregulated genes shared only by P3 and P4, including *SLAMF7*, whose activation was  
375 recently described to downregulate CCR5 on monocytes and reduced their infection capacity by  
376 HIV<sup>83</sup>, suggesting a potential difference in monocyte susceptibility and phenotype in these  
377 individuals during hyper-acute infection. Moreover, referring back to the initial cell type clustering  
378 of our data (Fig. S1), we noted that the peak response monocytes in P3 (0 weeks) clustered  
379 separately from other monocytes, and that P4 made up >75% of the anti-viral monocytes detected  
380 at 1-week post-infection. Identifying a potential correlate of future viral control otherwise obscured  
381 by bulk transcriptomics and sparse longitudinal sampling, we next searched for other unique  
382 immune responses enriched in either or both of the two controllers.

383

384 **Future controllers exhibit higher frequencies of proliferating CTLs and a precocious**  
385 **subset of NK cells before traditional HIV-specific CD8+ T cells**

386 As CD8+ T cells are known to play a part in controlling chronic HIV infection<sup>82,84,85</sup>, we  
387 turned to the CTLs in our study to look for differences between the individuals who controlled  
388 infection long-term and those who did not. Through our module discovery approach, we found

389 that CTLs produced increasing levels of *PRF1* and *GZMB* along the course of hyper-acute  
390 infection (Fig. 3C). Further unsupervised and directed approaches did not elucidate meaningful  
391 or significant differences in CTL responses across individuals by outcome of viral control (Fig.  
392 S10A-B and Table S7).

393 Recently, we demonstrated that, in most individuals in the FRESH study, a majority of  
394 proliferating CTLs in hyper-acute infection are HIV-specific by tetramer staining<sup>86</sup>. Therefore, we  
395 turned to the proliferating T cells in our study to look for differences in response based on long-  
396 term viral control. *En masse*, the proliferating T cells expressed similar levels of cytotoxic genes  
397 as non-proliferating CTLs (Fig. S10C). DE analysis highlighted genes associated with cell-cycle  
398 (e.g. *STMN1*, *HIST1H1B*, *MKI67*) and memory (e.g. *IL7R*, *KLRB1*) (see Fig. S10D and table S7)  
399 for proliferating and non-proliferating CTLs, respectively. While sparsely detected due to the  
400 method of library construction in Seq-Well, we did measure a limited number of TCR variable  
401 genes in the proliferating CTLs (Fig S10E). In fact, we note enrichment of TRBV and TRAV genes  
402 known to construct prevalent CDR3 sequences that bind common HIV epitopes<sup>87,88</sup>: *TRBV28*  
403 (QW9/FL8/KF11/KK10/NV9,  $\chi^2$  test  $p=2.4*10^{-26}$ ), *TRAV4* (KK10,  $\chi^2$  test  $p=3.5*10^{-6}$ ), and *TRBV20-*  
404 1 (KK10/KF11/GY9/NV9,  $\chi^2$  test  $p=0.059$ ). Our single-cell data here expand our recently  
405 published bulk RNA-Seq data on HIV-specific CTLs in this cohort<sup>89</sup>, but also enable us to elucidate  
406 heterogeneity in this proliferating cytotoxic response as a function of time.

407 Grouping proliferating T cells with the other CTLs, we sought to understand if these two  
408 controllers demonstrated differences in the frequency of proliferating T cells among the total CTL  
409 pool over time. Strikingly, both controllers (P3 & P4) displayed much higher frequencies of  
410 proliferating T cells within the first month of infection (Fig. 5A). While all four individuals developed  
411 proliferating T cells at 1-week post HIV detection, P3 and P4 exhibited a higher fraction of these  
412 cells 1 week after HIV detection (30-40%).

413 We next utilized unsupervised analyses to explore differences in proliferating T cell  
414 responses over time among individuals (Fig. 5B, Fig. S10F). Proliferating T cells captured at 1-  
415 week post-infection strongly separated in PCA across both PC1 and PC2 ( $p < 0.001$ ). Clustering  
416 over all proliferating T cells (see Methods), we identified four clusters of cells with distinct gene  
417 programs (see Fig. 5C and table S7): traditional CD8+ T cells (1-red), hyper-proliferative CD8+ T  
418 cells (2-green), naïve CD4+ T cells (3-cyan), and a subset of cells that is CD8- but *TRDC*+ and  
419 *FCGR3A*+ (CD16) (4-lilac). A recent scRNA-Seq study on cytotoxic innate-ness looked at  
420 cytotoxic  $\gamma\delta$ T and NK cells in healthy humans, noting basal levels of *TRDC* in both cell-types<sup>21</sup>.  
421 To determine whether these *TRDC*<sup>+</sup>*CD16*<sup>+</sup> cells were  $\gamma\delta$ T or NK cells, we scored them, as well as

422 non-proliferating CTLs and NK cells, against gene signatures described in that study (Fig. S10G).  
423 Based on score similarity to NK cells, and the relative down-regulation of CD3 compared to the  
424 other proliferating T cell subsets (Wilcoxon rank sum test; *CD3D*:  
425  $\log(\text{FC}) = -0.895$ ,  $q = 2.7 \times 10^{-42}$ ; *CD3G*:  $\log(\text{FC}) = -0.923$ ,  $q = 8.9 \times 10^{-37}$ ), we determine cluster 4  
426 (lilac) to be proliferating NK cells. Looking at the distribution of timepoints within each of these  
427 clusters, this NK cluster (4-lilac) contained the highest proportion of cells assayed at HIV detection  
428 and 1 week thereafter (Fig. 5D,E). Within these earliest proliferating NK cells, the majority were  
429 detected from P3 and P4. Together, these data suggest that individuals who go on control HIV  
430 infection without ART exhibit a subset of proliferative, cytotoxic NK cells before the majority of  
431 HIV-specific CD8+ T cells arise. Thus, investigating the classically induced cytotoxic cells in viral  
432 infection on a single-cell level revealed unappreciated heterogeneity in the anti-viral response,  
433 implicating innate immune responses in controlling infection.

434

### 435 ***Discussion***

436 Here we have applied both unsupervised and directed approaches to a unique longitudinal  
437 human infection data set to characterize conserved immune response dynamics, as well as early  
438 cellular events associated with the individuals studied here who go on to control infection without  
439 treatment. Sampling prior to and immediately upon HIV infection, we assayed longitudinal PBMC  
440 samples in four individuals from a prospective cohort, the FRESH Study<sup>16,17</sup> using Seq-Well<sup>18</sup>.  
441 This systems-level approach revealed parameters shared across all cell types examined (e.g.,  
442 response to IFN), as well as subtle variations among cellular types and individuals missed in  
443 previous bulk studies of infection. Further, it defined cell-type specific responses (e.g.,  
444 inflammatory induction of CD4+ T cells), and their interaction dynamics following infection.  
445 Moreover, leveraging the resolution and high-throughput capability of scRNA-Seq methods, we  
446 were able to uncover previously unappreciated cellular features in the PBMCs of two individuals  
447 who went on to control infection naturally, including subsets of poly-functional monocytes and  
448 proliferating NK cells limited to hyper-acute infection, that may correspond to better infection  
449 outcome.

450 To systematically identify immune cells responding with similar temporal dynamics, we  
451 adapted WGCNA<sup>26,27</sup> (Fig. 2A and see Methods) to discover modules of genes that significantly  
452 changed in expression within a given cell type over time. Cellular responses to infection can  
453 happen on the order of hours to days; therefore, even with the biweekly HIV testing in the FRESH  
454 Study, we anticipated these individuals would not align immune responses in absolute time. After

455 applying our module analysis, the strongest and most pervasive module across cell types and all  
456 individuals assayed was the interferon induced anti-viral response (Fig. 2D). While known to be  
457 a key factor in controlling HIV replication<sup>30,65</sup> and the major response in NHP SIV infection  
458 models<sup>52,90</sup>, the timing of response and extent to which it pervades all peripheral cell subsets in  
459 humans has not yet been described. Of note, both controllers (P3 & P4) exhibited interferon  
460 response modules the week before peak viremia, consistent with the faster resolution of interferon  
461 response in natural SIV hosts compared to non-natural hosts<sup>46-49</sup>. Moreover, multiple modules  
462 from P3 & P4 uniquely contained *APOBEC3A*, shown to restrict HIV infection in myeloid cells<sup>91</sup>,  
463 and *IFITM1* and *IFITM3* which can inhibit HIV translation in transfected cells *in-vitro*<sup>92</sup>.

464 Due to our ability to determine enriched modules within individual cells, we were able to  
465 unveil a second layer of regulation, which might otherwise be drowned out by the overwhelming  
466 IFN signature (Fig. 3F-H). This highlighted putative upstream drivers that are unique to CD4+ T  
467 cells, monocytes, NK cells, or shared amongst many cell types. Downstream genes (many  
468 shared) were significantly enriched for many known drivers of lymphocyte proliferation,  
469 emphasizing the presence of mounting large cytotoxic responses in more than just HIV-specific  
470 CD8<sup>+</sup> T cells during acute infection. Some of these molecules were also upstream of CD4<sup>+</sup> T cells,  
471 potentially increasing their susceptibility to infection (IL-15)<sup>69</sup> and inducing maturation (IL-2)<sup>67</sup> and  
472 differentiation (IL-4)<sup>93</sup>. Cell-type specific drivers, like IL-1B & TNF upstream of CD4+ T cells, also  
473 suggest T helper subset differentiation during this time frame<sup>70</sup>. However, the functional capacity  
474 of CD4<sup>+</sup> T cells to coordinate productive CD8<sup>+</sup> T cells during hyper-acute HIV infection has yet to  
475 be tested. Though we did not ascribe the relationships between all cell types and their immune  
476 modulators, this integrated multi-cellular analysis lays the foundation for future characterization  
477 of the complex, dynamic immune responses to an infection. A potential method to pinpoint the  
478 effects of the various cytokines produced in acute infection might utilize *in-vitro* assays that couple  
479 PBMCs from healthy individuals with and without autologously HIV infected CD4+ T cells.

480 Empowered by our single-cell resolution and cognizant of the role HIV-specific T cells play  
481 in long-term control<sup>82,84,94</sup>, we were intrigued to find not only higher frequencies of proliferating  
482 CTLs in P3/P4, but also the presence of a subset of a previously unappreciated proliferating NK  
483 cells preceding the well-described HIV-specific responses (Fig. 5C-E), given the multi-faceted  
484 role of NK cells in viral control<sup>64</sup>. Assaying cells from controllers *in-vitro* showed that NK cells were  
485 equivalent to CD8<sup>+</sup> T cells in inhibiting viral replication<sup>95</sup>; however recent work has demonstrated  
486 CD11b<sup>+</sup>CD57<sup>-</sup>CD161<sup>+</sup>Siglec-7<sup>+</sup> NK cells to be more abundant in elite controllers compared to  
487 those who progress<sup>96</sup>. The proliferating NK cells measured here also express high levels of

488 CD161 (*KLRB1*), associated with the production of IFN- $\gamma$  in response to IL-12 and IL-18<sup>97</sup>. Antigen  
489 specific expansion of cytotoxic NK cells has been shown to occur in hCMV<sup>98,99</sup>, hantavirus<sup>100</sup>, and  
490 SIV<sup>101</sup> as a “memory-like” response; however, we do not measure changes in NKG2C (*KLRC1*)  
491 here. Lacking the opportunity to assay previous viral exposure in these individuals, we cannot  
492 comment on whether these cells might be proliferating in response to a previously encountered  
493 antigen from HIV or a similar retrovirus. We hypothesize that a similar phenotype of proliferating  
494 NK cells may arise in response to re-encountering antigen after early ART. To test this, one could  
495 examine the killing capacity of NK and CD8 $^+$  T cells *in-vitro* from individuals treated at various  
496 stages of acute and chronic infection, given sample availability.

497 Collectively, our single-cell transcriptional study of hyper-acute and acute HIV infection in  
498 FRESH provides several key insights into the dynamics of host-immune responses to infection  
499 on a systems-level. It also affords a key reference data set for studying the earliest moments of  
500 viral infection after detection. While limited sample availability and the inability to recreate a  
501 prospective study like this (since immediate ART is now standard of care) preclude strong  
502 associations with clinical parameters across individuals, we are able to nominate potential early  
503 responses that may inform long-term viral control and thus guide HIV vaccine efforts. Although  
504 preliminary, many of these observations can be validated in NHP models via proper selection of  
505 natural and unnatural hosts/virus strains. Future work in FRESH will seek test the effects of early  
506 administered ART on these longitudinal HIV response dynamics, while work in other viral and  
507 bacterial infections in additional human cohorts will enable assessment of the broad utility of the  
508 methods and features described here.

## 509 REFERENCES

- 510 1. Querec, T. D. *et al.* Systems biology approach predicts immunogenicity of the yellow fever  
511 vaccine in humans. *Nature Immunology* **10**, 116–125 (2009).
- 512 2. Li, C. *et al.* Host Regulatory Network Response to Infection with Highly Pathogenic H5N1  
513 Avian Influenza Virus. *Journal of Virology* **85**, 10955–10967 (2011).
- 514 3. Gaublomme, J. T. *et al.* Single-Cell Genomics Unveils Critical Regulators of Th17 Cell  
515 Pathogenicity. *Cell* **163**, 1400–1412 (2015).
- 516 4. Jerby-Arnon, L. *et al.* A Cancer Cell Program Promotes T Cell Exclusion and Resistance to  
517 Checkpoint Blockade. *Cell* **175**, 984–997.e24 (2018).
- 518 5. Tirosh, I. *et al.* Dissecting the multicellular ecosystem of metastatic melanoma by single-  
519 cell RNA-seq. *Science* **352**, 189–196 (2016).
- 520 6. Ledergor, G. *et al.* Single cell dissection of plasma cell heterogeneity in symptomatic and  
521 asymptomatic myeloma. *Nat. Med.* **24**, 1867–1876 (2018).
- 522 7. Martin-Gayo, E. *et al.* A Reproducibility-Based Computational Framework Identifies an  
523 Inducible, Enhanced Antiviral State in Dendritic Cells from HIV-1 Elite Controllers. *Genome  
524 Biology* **19**, 10 (2018).
- 525 8. Ordovas-Montanes, J. *et al.* Allergic inflammatory memory in human respiratory epithelial  
526 progenitor cells. *Nature* **560**, 649 (2018).

527 9. Steuerman, Y. *et al.* Dissection of Influenza Infection In Vivo by Single-Cell RNA  
528 Sequencing. *Cell Syst* **6**, 679-691.e4 (2018).

529 10. Sade-Feldman, M. *et al.* Defining T Cell States Associated with Response to Checkpoint  
530 Immunotherapy in Melanoma. *Cell* **175**, 998-1013.e20 (2018).

531 11. Davie, K. *et al.* A Single-Cell Transcriptome Atlas of the Aging Drosophila Brain. *Cell* **174**,  
532 982-998.e20 (2018).

533 12. Cao, J. *et al.* The single-cell transcriptional landscape of mammalian organogenesis.  
534 *Nature* **566**, 496 (2019).

535 13. Arts, E. J. & Hazuda, D. J. HIV-1 Antiretroviral Drug Therapy. *Cold Spring Harb Perspect  
536 Med* **2**, a007161 (2012).

537 14. Venter, W. D. F., Cowan, F., Black, V., Rebe, K. & Bekker, L.-G. Pre-exposure prophylaxis  
538 in Southern Africa: feasible or not? *Journal of the International AIDS Society* **18**, 19979  
539 (2015).

540 15. Joint United Nations Programme on HIV/AIDS (UNAIDS). *UNAIDS Data 2018*. (Joint  
541 United Nations Programme on HIV/AIDS (UNAIDS), 2018).

542 16. Dong, K. L. *et al.* Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk  
543 women in South Africa: a prospective cohort study. *The Lancet HIV* **5**, e35–e44 (2018).

544 17. Ndung'u, T., Dong, K. L., Kwon, D. S. & Walker, B. D. A FRESH approach: Combining  
545 basic science and social good. *Science Immunology* **3**, eaau2798 (2018).

546 18. Gierahn, T. M. *et al.* Seq-Well: portable, low-cost RNA sequencing of single cells at high  
547 throughput. *Nature Methods* **14**, 395–398 (2017).

548 19. Villani, A.-C. *et al.* Single-cell RNA-seq reveals new types of human blood dendritic cells,  
549 monocytes, and progenitors. *Science* **356**, (2017).

550 20. Kang, H. M. *et al.* Multiplexed droplet single-cell RNA-sequencing using natural genetic  
551 variation. *Nature Biotechnology* **36**, 89–94 (2018).

552 21. Gutierrez-Arcelus, M. *et al.* Lymphocyte innateness defined by transcriptional states  
553 reflects a balance between proliferation and effector functions. *Nat Commun* **10**, 687  
554 (2019).

555 22. Douek, D. C., Picker, L. J. & Koup, R. A. T cell dynamics in HIV-1 infection. *Annu. Rev.  
556 Immunol.* **21**, 265–304 (2003).

557 23. Sprenger, H. *et al.* Selective induction of monocyte and not neutrophil-attracting  
558 chemokines after influenza A virus infection. *J. Exp. Med.* **184**, 1191–1196 (1996).

559 24. Carlin, L. E., Hemann, E. A., Zacharias, Z. R., Heusel, J. W. & Legge, K. L. Natural Killer  
560 Cell Recruitment to the Lung During Influenza A Virus Infection Is Dependent on CXCR3,  
561 CCR5, and Virus Exposure Dose. *Front Immunol* **9**, (2018).

562 25. Salazar-Mather, T. P., Orange, J. S. & Biron, C. A. Early murine cytomegalovirus (MCMV)  
563 infection induces liver natural killer (NK) cell inflammation and protection through  
564 macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. *J. Exp. Med.*  
565 **187**, 1–14 (1998).

566 26. Zhang, B. & Horvath, S. A general framework for weighted gene co-expression network  
567 analysis. *Stat Appl Genet Mol Biol* **4**, Article17 (2005).

568 27. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network  
569 analysis. *BMC Bioinformatics* **9**, 559 (2008).

570 28. Mellors, J. W. *et al.* Quantitation of HIV-1 RNA in plasma predicts outcome after  
571 seroconversion. *Ann. Intern. Med.* **122**, 573–579 (1995).

572 29. Lavreys, L. *et al.* Higher Set Point Plasma Viral Load and More-Severe Acute HIV Type 1  
573 (HIV-1) Illness Predict Mortality among High-Risk HIV-1-Infected African Women. *Clin  
574 Infect Dis* **42**, 1333–1339 (2006).

575 30. Grandvaux, N., tenOever, B. R., Servant, M. J. & Hiscott, J. The interferon antiviral  
576 response: from viral invasion to evasion. *Curr. Opin. Infect. Dis.* **15**, 259–267 (2002).

577 31. Samarajiwa, S. A., Forster, S., Auchettl, K. & Hertzog, P. J. INTERFEROME: the database  
578 of interferon regulated genes. *Nucleic Acids Res* **37**, D852–D857 (2009).

579 32. Schoggins, J. W. & Rice, C. M. Interferon-stimulated genes and their antiviral effector  
580 functions. *Curr Opin Virol* **1**, 519–525 (2011).

581 33. Corleis, B. *et al.* Early type I Interferon response induces upregulation of human  $\beta$ -defensin  
582 1 during acute HIV-1 infection. *PLoS ONE* **12**, e0173161 (2017).

583 34. Vargas-Inchaustegui, D. A. *et al.* CXCL10 production by human monocytes in response to  
584 Leishmania braziliensis infection. *Infect. Immun.* **78**, 301–308 (2010).

585 35. Wu, L. & KewalRamani, V. N. Dendritic-cell interactions with HIV: infection and viral  
586 dissemination. *Nat. Rev. Immunol.* **6**, 859–868 (2006).

587 36. Luban, J. Innate immune sensing of HIV-1 by dendritic cells. *Cell Host Microbe* **12**, 408–  
588 418 (2012).

589 37. Ng, D. & Gommerman, J. L. The Regulation of Immune Responses by DC Derived Type I  
590 IFN. *Front Immunol* **4**, (2013).

591 38. Riou, C. *et al.* Distinct kinetics of Gag-specific CD4+ and CD8+ T cell responses during  
592 acute HIV-1 infection. *J. Immunol.* **188**, 2198–2206 (2012).

593 39. Schrum, A. G. & Turka, L. A. The Proliferative Capacity of Individual Naive CD4+T Cells Is  
594 Amplified by Prolonged T Cell Antigen Receptor Triggering. *J Exp Med* **196**, 793–803  
595 (2002).

596 40. Kurtulus, S. *et al.* TIGIT predominantly regulates the immune response via regulatory T  
597 cells. *J Clin Invest* **125**, 4053–4062 (2015).

598 41. Samten, B. CD52 as both a marker and an effector molecule of T cells with regulatory  
599 action: Identification of novel regulatory T cells. *Cell Mol Immunol* **10**, 456–458 (2013).

600 42. Lugli, E., Marcenaro, E. & Mavilio, D. NK Cell Subset Redistribution during the Course of  
601 Viral Infections. *Front Immunol* **5**, (2014).

602 43. Reeves, R. K., Evans, T. I., Gillis, J. & Johnson, R. P. Simian Immunodeficiency Virus  
603 Infection Induces Expansion of 4 7+ and Cytotoxic CD56+ NK Cells. *Journal of Virology*  
604 **84**, 8959–8963 (2010).

605 44. Carlin-Brown, L. E., Fullenkamp, C. A., McGill, J., Legge, K. L. & Heusel, J. W. Adoptive  
606 transfer and pulmonary homing of NK cells rescues NK cell-deficient mice from early  
607 lethality during acute influenza A virus infection (130.11). *The Journal of Immunology* **182**,  
608 130.11-130.11 (2009).

609 45. Mehla, R. & Ayyavoo, V. Gene Array Studies in HIV-1 Infection. *Curr HIV/AIDS Rep* **9**, 34–  
610 43 (2012).

611 46. Lederer, S. *et al.* Transcriptional profiling in pathogenic and non-pathogenic SIV infections  
612 reveals significant distinctions in kinetics and tissue compartmentalization. *PLoS Pathog.*  
613 **5**, e1000296 (2009).

614 47. Bosinger, S. E. *et al.* Global genomic analysis reveals rapid control of a robust innate  
615 response in SIV-infected sooty mangabeys. *J. Clin. Invest.* **119**, 3556–3572 (2009).

616 48. Yang, Z.-W. *et al.* Coexpression Network Analysis of Benign and Malignant Phenotypes of  
617 SIV-Infected Sooty Mangabey and Rhesus Macaque. *PLoS ONE* **11**, e0156170 (2016).

618 49. Jacquelin, B. *et al.* Nonpathogenic SIV infection of African green monkeys induces a  
619 strong but rapidly controlled type I IFN response. *J. Clin. Invest.* **119**, 3544–3555 (2009).

620 50. Solis, M. *et al.* RIG-I-Mediated Antiviral Signaling Is Inhibited in HIV-1 Infection by a  
621 Protease-Mediated Sequestration of RIG-I. *Journal of Virology* **85**, 1224–1236 (2011).

622 51. Farrar, J. D. *et al.* Selective loss of type I interferon-induced STAT4 activation caused by a  
623 minisatellite insertion in mouse Stat2. *Nature Immunology* **1**, 65 (2000).

624 52. Bosinger, S. E. *et al.* Intact Type I Interferon Production and IRF7 Function in Sooty  
625 Mangabeys. *PLoS Pathogens* **9**, e1003597 (2013).

626 53. Honda, K., Takaoka, A. & Taniguchi, T. Type I Interferon Gene Induction by the Interferon  
627 Regulatory Factor Family of Transcription Factors. *Immunity* **25**, 349–360 (2006).

628 54. Sato, M. *et al.* Positive feedback regulation of type I IFN genes by the IFN-inducible  
629 transcription factor IRF-7. *FEBS Lett.* **441**, 106–110 (1998).

630 55. Ma, F. *et al.* Positive Feedback Regulation of Type I IFN Production by the IFN-Inducible  
631 DNA Sensor cGAS. *The Journal of Immunology* **194**, 1545–1554 (2015).

632 56. Michalska, A., Blaszczyk, K., Wesoly, J. & Bluyssen, H. A. R. A Positive Feedback  
633 Amplifier Circuit That Regulates Interferon (IFN)-Stimulated Gene Expression and Controls  
634 Type I and Type II IFN Responses. *Front. Immunol.* **9**, (2018).

635 57. O'Brien, M., Manches, O. & Bhardwaj, N. Plasmacytoid Dendritic Cells in HIV Infection.  
636 *Adv Exp Med Biol* **762**, 71–107 (2013).

637 58. Trombetta, J. J. *et al.* Preparation of Single-Cell RNA-Seq Libraries for Next Generation  
638 Sequencing. *Curr Protoc Mol Biol* **107**, (2014).

639 59. Futschik, M. E. & Carlisle, B. Noise-robust soft clustering of gene expression time-course  
640 data. *J Bioinform Comput Biol* **3**, 965–988 (2005).

641 60. Kumar, L. & E. Futschik, M. Mfuzz: A software package for soft clustering of microarray  
642 data. *Bioinformation* **2**, 5–7 (2007).

643 61. Athanasiadis, E. I. *et al.* Single-cell RNA-sequencing uncovers transcriptional states and  
644 fate decisions in haematopoiesis. *Nature Communications* **8**, 2045 (2017).

645 62. Sloan, R. D. *et al.* Productive Entry of HIV-1 during Cell-to-Cell Transmission via Dynamin-  
646 Dependent Endocytosis. *Journal of Virology* **87**, 8110–8123 (2013).

647 63. Gulzar, N. & Copeland, K. F. T. CD8+ T-cells: function and response to HIV infection. *Curr.*  
648 *HIV Res.* **2**, 23–37 (2004).

649 64. Scully, E. & Alter, G. NK Cells in HIV Disease. *Curr HIV/AIDS Rep* **13**, 85–94 (2016).

650 65. Cheng, L. *et al.* Type I interferons suppress viral replication but contribute to T cell  
651 depletion and dysfunction during chronic HIV-1 infection. *JCI Insight* **2**,

652 66. Zhen, A. *et al.* Targeting type I interferon-mediated activation restores immune function in  
653 chronic HIV infection. *J. Clin. Invest.* **127**, 260–268 (2017).

654 67. Sereti, I. *et al.* IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated  
655 with long-term decreases in T-cell proliferation. *Blood* **104**, 775–780 (2004).

656 68. Anton, O. M., Vielkind, S., Peterson, M. E., Tagaya, Y. & Long, E. O. NK Cell Proliferation  
657 Induced by IL-15 Transpresentation Is Negatively Regulated by Inhibitory Receptors. *The*  
658 *Journal of Immunology* **195**, 4810–4821 (2015).

659 69. Manganaro, L. *et al.* IL-15 regulates susceptibility of CD4+ T cells to HIV infection. *PNAS*  
660 **115**, E9659–E9667 (2018).

661 70. Hebel, K. *et al.* IL-1 and TGF- $\beta$  Act Antagonistically in Induction and Differentially in  
662 Propagation of Human Proinflammatory Precursor CD4+ T Cells. *The Journal of*  
663 *Immunology* **187**, 5627–5635 (2011).

664 71. Harton, J. A. & Ting, J. P.-Y. Class II Transactivator: Mastering the Art of Major  
665 Histocompatibility Complex Expression. *Mol Cell Biol* **20**, 6185–6194 (2000).

666 72. Carbotti, G. *et al.* IL-27 mediates HLA class I up-regulation, which can be inhibited by the  
667 IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells. *J Exp Clin Cancer Res* **36**,  
668 140 (2017).

669 73. Zeng, M. *et al.* Lymphoid Tissue Damage in HIV-1 Infection Depletes Naïve T Cells and  
670 Limits T Cell Reconstitution after Antiretroviral Therapy. *PLOS Pathogens* **8**, e1002437  
671 (2012).

672 74. Son, Y. I. *et al.* Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity,  
673 interferon-gamma production, and expansion of natural killer cells. *Cancer Res.* **61**, 884–  
674 888 (2001).

675 75. Petes, C., Mariani, M. K., Yang, Y., Grandvaux, N. & Gee, K. Interleukin (IL)-6 Inhibits IL-  
676 27- and IL-30-Mediated Inflammatory Responses in Human Monocytes. *Front Immunol* **9**,  
677 (2018).

678 76. Stacey, A. R. *et al.* Induction of a striking systemic cytokine cascade prior to peak viremia  
679 in acute human immunodeficiency virus type 1 infection, in contrast to more modest and  
680 delayed responses in acute hepatitis B and C virus infections. *J. Virol.* **83**, 3719–3733  
681 (2009).

682 77. Robertson, M. J. Role of chemokines in the biology of natural killer cells. *J. Leukoc. Biol.*  
683 **71**, 173–183 (2002).

684 78. Tilton, J. C. *et al.* Diminished Production of Monocyte Proinflammatory Cytokines during  
685 Human Immunodeficiency Virus Viremia Is Mediated by Type I Interferons. *Journal of*  
686 *Virology* **80**, 11486–11497 (2006).

687 79. Porcheray, F., Samah, B., Léone, C., Dereuddre-Bosquet, N. & Gras, G. Macrophage  
688 activation and human immunodeficiency virus infection: HIV replication directs  
689 macrophages towards a pro-inflammatory phenotype while previous activation modulates  
690 macrophage susceptibility to infection and viral production. *Virology* **349**, 112–120 (2006).

691 80. Ellery, P. J. *et al.* The CD16+ Monocyte Subset Is More Permissive to Infection and  
692 Preferentially Harbors HIV-1 In Vivo. *The Journal of Immunology* **178**, 6581–6589 (2007).

693 81. Deeks, S. G. & Walker, B. D. Human immunodeficiency virus controllers: mechanisms of  
694 durable virus control in the absence of antiretroviral therapy. *Immunity* **27**, 406–416 (2007).

695 82. Hersperger, A. R. *et al.* Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite  
696 controllers is associated with T-bet expression. *Blood* **117**, 3799–3808 (2011).

697 83. O'Connell, P. *et al.* SLAMF7 Is a Critical Negative Regulator of IFN- $\alpha$ -Mediated CXCL10  
698 Production in Chronic HIV Infection. *The Journal of Immunology* **202**, 228–238 (2019).

699 84. Hersperger, A. R. *et al.* Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a  
700 correlate of HIV elite control. *PLoS Pathog.* **6**, e1000917 (2010).

701 85. Koup, R. A. *et al.* Temporal association of cellular immune responses with the initial control  
702 of viremia in primary human immunodeficiency virus type 1 syndrome. *Journal of Virology*  
703 **68**, 4650–4655 (1994).

704 86. Ndhlovu, Z. M. *et al.* Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute  
705 HIV Infection Impact Viral Set Point. *Immunity* **43**, 591–604 (2015).

706 87. Conrad, J. A. *et al.* Dominant clonotypes within HIV-specific T cell responses are PD-1hi  
707 and CD127low and display reduced variant cross-reactivity. *J Immunol* **186**, 6871–6885  
708 (2011).

709 88. Bockel, D. J. van *et al.* Persistent Survival of Prevalent Clonotypes within an  
710 Immunodominant HIV Gag-Specific CD8+ T Cell Response. *The Journal of Immunology*  
711 **186**, 359–371 (2011).

712 89. Ndhlovu, Z. M. *et al.* Augmentation of HIV-specific T cell function by immediate treatment  
713 of hyperacute HIV-1 infection. *Science Translational Medicine*

714 90. Sandler, N. G. *et al.* Type I interferon responses in rhesus macaques prevent SIV infection  
715 and slow disease progression. *Nature* **511**, 601–605 (2014).

716 91. Berger, G. *et al.* APOBEC3A Is a Specific Inhibitor of the Early Phases of HIV-1 Infection in  
717 Myeloid Cells. *PLOS Pathogens* **7**, e1002221 (2011).

718 92. Lee, W.-Y. J., Fu, R. M., Liang, C. & Sloan, R. D. IFITM proteins inhibit HIV-1 protein  
719 synthesis. *Scientific Reports* **8**, 14551 (2018).

720 93. Silva-Filho, J. L., Caruso-Neves, C. & Pinheiro, A. A. S. IL-4: an important cytokine in  
721 determining the fate of T cells. *Biophys Rev* **6**, 111–118 (2014).

722 94. Gaiha, G. *et al.* Structural Topology Defines Protective CD8+ T cell Epitopes in the HIV  
723 Proteome. *Science*

724 95. O'Connell, K. A., Han, Y., Williams, T. M., Siliciano, R. F. & Blankson, J. N. Role of Natural  
725 Killer Cells in a Cohort of Elite Suppressors: Low Frequency of the Protective KIR3DS1  
726 Allele and Limited Inhibition of Human Immunodeficiency Virus Type 1 Replication In Vitro.  
727 *Journal of Virology* **83**, 5028–5034 (2009).

728 96. Pohlmeier, C. W. *et al.* Identification of NK cell subpopulations that differentiate HIV-  
729 infected subject cohorts with diverse level of virus control. *Journal of Virology* **JVI**.01790-18  
730 (2019). doi:10.1128/JVI.01790-18

731 97. Kurioka, A. *et al.* CD161 Defines a Functionally Distinct Subset of Pro-Inflammatory  
732 Natural Killer Cells. *Front Immunol* **9**, (2018).

733 98. Foley, B. *et al.* Natural Killer (NK) Cells Respond to CMV Reactivation After Allogeneic  
734 Transplantation with An Increase in NKG2C+CD57+ Self-KIR+ NK Cells with Potent IFN $\gamma$   
735 Production. *Blood* **118**, 356–356 (2011).

736 99. Foley, B. *et al.* Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells  
737 Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen. *The  
738 Journal of Immunology* **189**, 5082–5088 (2012).

739 100. Björkström, N. K. *et al.* Rapid expansion and long-term persistence of elevated NK cell  
740 numbers in humans infected with hantavirus. *J Exp Med* **208**, 13–21 (2011).

741 101. Reeves, R. K. *et al.* Antigen-specific NK cell memory in rhesus macaques. *Nat. Immunol.*  
742 **16**, 927–932 (2015).

743 102. Butler, A., Hoffman, P., Smibert, P., Papalex, E. & Satija, R. Integrating single-cell  
744 transcriptomic data across different conditions, technologies, and species. *Nature  
745 Biotechnology* **36**, 411–420 (2018).

746 103. Linderman, G. C., Rachh, M., Hoskins, J. G., Steinerberger, S. & Kluger, Y. Fast  
747 interpolation-based t-SNE for improved visualization of single-cell RNA-seq data. *Nature  
748 Methods* **16**, 243 (2019).

749 104. Liberzon, A. *et al.* The Molecular Signatures Database Hallmark Gene Set Collection. *Cell  
750 Systems* **1**, 417–425 (2015).

751 105. Godec, J. *et al.* Compendium of Immune Signatures Identifies Conserved and Species-  
752 Specific Biology in Response to Inflammation. *Immunity* **44**, 194–206 (2016).

753 106. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or  
754 without a reference genome. *BMC Bioinformatics* **12**, 323 (2011).

755 107. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-  
756 Seq. *Bioinformatics* **25**, 1105–1111 (2009).

757 108. Beignon, A.-S. *et al.* Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-  
758 like receptor-viral RNA interactions. *J. Clin. Invest.* **115**, 3265–3275 (2005).

759 109. Malleret, B. *et al.* Primary infection with simian immunodeficiency virus: plasmacytoid  
760 dendritic cell homing to lymph nodes, type I interferon, and immune suppression. *Blood*  
761 **112**, 4598–4608 (2008).

762 110. Becker, M., Hobeika, E., Jumaa, H., Reth, M. & Maity, P. C. CXCR4 signaling and function  
763 require the expression of the IgD-class B-cell antigen receptor. *Proc Natl Acad Sci U S A*  
764 **114**, 5231–5236 (2017).

765 111. Wagner, E. F. *et al.* Novel Diversity in IL-4-Mediated Responses in Resting Human Naïve  
766 B Cells Versus Germinal Center/Memory B Cells. *The Journal of Immunology* **165**, 5573–  
767 5579 (2000).

768 112. Moir, S. & Fauci, A. S. B cells in HIV infection and disease. *Nat Rev Immunol* **9**, 235–245  
769 (2009).

770 113. Mabuka, J. M. *et al.* Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection  
771 Predicts Emergence of Cross-Neutralizing Antibodies. *Front Immunol* **8**, 1104 (2017).

772 114. Bradley, T. *et al.* Pentavalent HIV-1 vaccine protects against simian-human  
773 immunodeficiency virus challenge. *Nat Commun* **8**, (2017).

774 115. Pauthner, M. G. *et al.* Vaccine-Induced Protection from Homologous Tier 2 SHIV  
775 Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers.  
776 *Immunity* **50**, 241-252.e6 (2019).

777

778 **ACKNOWLEDGEMENTS**

779 We thank the individuals who have participated in the FRESH Study, as well as the FRESH and  
780 HIV Pathogenesis Programme (HPP) staff; M. Waring, N. Bonheur, E. Koscher for flow cytometry  
781 and sorting services through the Ragon Institute Imaging Core-Flow Cytometry Facility; A.  
782 Piechocka-Trocha for sample handling and reagent preparation; M. Cole and N. Yosef for advice  
783 on computational methodology; D. Kwon, S. Bloom, M. Hayward for participant intake and STI  
784 data; M. Carrington and A. Bashirova for HLA genotyping; S. Rasehlo and N. A. Akilimali for  
785 support with Luminex measurements; A. Leslie, H. Kløverpris, D. Lingwood, and S. Pillai for  
786 insightful discussions. This work was supported, in part, by the Searle Scholars Program, the  
787 Beckman Young Investigator Program, the Pew-Stewart Scholars Program for Cancer Research,  
788 a Sloan Fellowship in Chemistry, the NIH (2U19AI089992, 2R01HL095791, 1U54CA217377,  
789 2P01AI039671, 5U24AI118672, 2RM1HG006193, 1R33CA202820, 1R01AI138546,  
790 1R37AI067073, 1R01HL126554, 1R01DA046277, 1U2CCA23319501, K08 AI118538), the Bill  
791 and Melinda Gates Foundation (OPP1139972, OPP1202327, OPP1137006, OPP1202327,  
792 OPP1066973, OPP1146433), an NSF Graduate Student Fellowship Award, the Hugh Hampton  
793 Young Memorial Fund Fellowship, Gilead Sciences, Inc (Grant ID #00406), the International AIDS  
794 Vaccine Initiative (IAVI) (UKZNRSA1001), the South African National Research Foundation (grant  
795 #64809), the NIAID (R37AI067073), the Witten Family Foundation, Dan and Marjorie Sullivan  
796 Foundation, the Mark and Lisa Schwartz Foundation, Ursula Brunner, the AIDS Healthcare  
797 Foundation, and the Harvard University Center for AIDS Research (CFAR, P30 AI060354, which  
798 is supported by the following institutes and centers co-funded by and participating with the US  
799 National Institutes of Health: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC and OAR.), the  
800 Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa  
801 Initiative [grant # DEL-15-006]. The DELTAS Africa Initiative is an independent funding scheme  
802 of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in  
803 Africa (AES) and supported by the New Partnership for Africa's Development Planning and  
804 Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (grant #  
805 107752/Z/15/Z) and the United Kingdom (UK) government. The views expressed in this  
806 publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency,  
807 Wellcome Trust or the UK government. Raw data will be available through Database of  
808 Genotypes and Phenotypes (dbGaP), accession number pending.

809

810 **SUPPLEMENTARY INFORMATION**


811 Methods, supplementary discussion, and supplementary figures can be found in the  
812 Supplementary Information file. Supplementary tables are available upon request from the  
813 corresponding author: [shalek@mit.edu](mailto:shalek@mit.edu).

814

815

816


817



818

819 **Fig. 1: Longitudinal profiling of peripheral immune cells in hyper-acute and acute HIV-**  
 820 **infection by single-cell RNA-sequencing. (A)** Representation of the typical trajectory of HIV  
 821 viral load in the plasma during hyper-acute and acute HIV infection, and the timepoints sampled  
 822 in this study. Since participants are tested twice weekly, there is an uncertainty of up to 3 days in  
 823 where on the viral load curve the first detectable viremia occurs. The exact days sampled are  
 824 available in table S1. **(B)** Viral load and CD4 T cell count for the four individuals assayed in this  
 825 study. Dotted lines indicate a missing data point for the metric. **(C)** tSNE analysis of PBMCs from


826 all individuals and timepoints sampled (n=65,842). Cells are annotated based on differential  
827 expression analysis on orthogonally discovered clusters. (D) tSNE in C annotated by timepoint  
828 (left) and individual (right). (E) Scatter plot depicting the correlation between cell frequencies of  
829 CD4+ and CD8+ T cells measured by Seq-Well and FACS. R-squared values reflect variance  
830 described by a linear model. \* p < 0.05; \*\* p < 0.01; \*\*\* p < 0.001.  
831



832

833 **Fig. 2: Gene module discovery reveals ubiquitous response to interferon with cell type**  
 834 **specific features. (A)** Schema depicting temporal gene module discovery (see **Methods**). This  
 835 procedure is repeated for each major cell type (monocytes, CD4+ T cells, CTLs, proliferating T  
 836 cells, NK cells, B cells, plasmablasts, and mDCs) on an individual-by-individual basis. **(B)** In P1,  
 837 six gene modules across multiple cell types exhibit similar temporal profiles with peak module  
 838 scores at the same timepoint as peak viremia is measured. **(C)** Number of occurrences of genes  
 839 across the modules in **B**. **(D)** Module scores for interferon response modules in each individual.  
 840 The timepoint where peak viral load occurs is indicated by a dotted line. **(E)** Luminex  
 841 measurements of IP10 (left) and MIG (right) in matching plasma samples. Points are averages of  
 842 duplicate measurements.


843



844


845 **Fig. 3: Modules with sustained expression conserved among individuals suggest shared**  
 846 **and cell type specific drivers of immune response.** Module Scores (left), gene overlaps  
 847 between modules (middle), and enriched pathways for each module (right) in (A) CD4+ T cells,  
 848 (B) monocytes, (C) CTLs, (D) NK cells, and (E) proliferating T cells. (F) Network of predicted  
 849 upstream drivers of modules in A-E. Nodes are colored by significance in each cell-type. Edge  
 850 width and color reflect the number of shared genes (width) in the gene sets of the upstream drivers  
 851 for a given cell-type (color; see Methods). (G) Median gene set scores for significantly temporally  
 852 variant ( $p < 0.05$ ) upstream drivers in P1. Scores are grouped by k-means clustering;  $k=5$ . (H)

853 Summary table of immune responses to related and distinct stimuli with similar temporal  
854 dynamics.



856 **Fig. 4: One individual who goes on to control infection presents a poly-functional subset**  
857 **of monocytes at HIV detection. (A)** Inflammatory and anti-viral scores of monocytes in P3 (left)  
858 and P1 (right) derived from gene lists created from merging modules among individuals. Ellipses  
859 drawn at 95% confidence interval for cells from each timepoint. **(B)** Principal component analysis  
860 (PCA) of all monocytes from P3 (left) and P1 (right). Density of cells in PC1 vs PC2 space  
861 annotated by timepoint are depicted, and the top loading genes for PC1 and PC2 are also  
862 annotated. **(C)** Heatmap of differentially expressed genes between monocytes at the peak  
863 response timepoint (0 weeks/1 week) vs pre-infection. Arrows indicate genes specific to P3 (dark-  
864 brown) and P1 (violet). **(D)** Enriched pathways for the differentially expressed genes in **C**, using  
865 the MSigDB Hallmark Gene Sets. **(E)** Viral load by RT-PCR of the plasma of the four individuals  
866 assayed out to 2.75 years. Controllers of HIV maintain levels of plasma viremia less than 1,000  
867 viral copies (vc)/mL. P1 initiated ART before the 2.3 year timepoint.

868



869

870 **Fig. 5: Future controllers exhibit higher frequencies of proliferating CTLs and a precocious**  
 871 **subset of NK cells 1 week after detection of HIV viremia. (A)** Proportion of proliferating T cells  
 872 **of total CTLs as a function of time and individual measured by Seq-Well. (B)** PCA of proliferating  
 873 **T cells from all four individuals. Cells assayed from the 1-week timepoint strongly separate along**  
 874 **PC1 and PC2; Mann Whitney-U Test, \*\*\* p < 0.001. (C)** SNN clustering over the top 6 PCs reveals  
 875 **four sub-clusters (left) with distinct gene programs (right). (D)** Percentage of cells in each sub-  
 876 **cluster by timepoint. (E)** Number of cells from each individual within the cells sampled at 0 weeks  
 877 **and 1 week in the NK cell cluster (4-lilac; black box in D).**